Get the latest news, insights, and market updates on KALV (KalVista Pharmaceuticals, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe
FRAMINGHAM, Mass. & SALISBURY, England, October 06, 2025--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data from its KONFIDENT and KONFIDENT-S studies of EKTERLY® (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema (HAE), presented at the 20th German Allergy Congress in Düsseldorf, Germany from October 2–4, 2025. Across multiple ePoster presentations, EKTERLY demonstrated the ability to rapidly halt the progression of HAE attacks, deliver fa Oct 6, 2025 - $KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FRAMINGHAM, Mass. & SALISBURY, England, October 03, 2025--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 30,000 shares of KalVista common stock on October 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock Oct 3, 2025 - $KALV
KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors
FRAMINGHAM, Mass. & SALISBURY, England, October 02, 2025--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the appointment of Bethany L. Sensenig to its Board of Directors, effective as of October 1, 2025. Ms. Sensenig was also appointed a member of the Audit Committee of the Board. In connection with Ms. Sensenig’s appointment to the Audit Committee, Nancy Stuart will transition off the Audit Committee but remains a member of the Board and continues to serve on the Nominating and C Oct 2, 2025 - $KALV
KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031
FRAMINGHAM, Mass. & SALISBURY, England, September 25, 2025--KalVista Pharmaceuticals, Inc. ("KalVista") (NASDAQ: KALV), announced today the pricing of its offering of $125.0 million aggregate principal amount of 3.250% Convertible Senior Notes due 2031 (the "notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The aggregate principal amount of the offering was Sep 25, 2025 - $KALV
KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes
FRAMINGHAM, Mass. & SALISBURY, England, September 24, 2025--KalVista Pharmaceuticals, Inc. ("KalVista") (NASDAQ: KALV) announced today that it intends to offer, subject to market conditions and other factors, $110.0 million aggregate principal amount of Convertible Senior Notes due 2031 (the "notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). KalVista also in Sep 24, 2025 - $KALV
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple